MT1X was overexpressed in many cancers, including breast cancer (Si and Lang, 2018), and was a prognostic marker for invasive ductal carcinoma (Zhang et al., 2000) and renal carcinoma (Ding et al., 2022). Here, MT1X is linked to breast cancer.